COVID-19 antibody test: Development of a unique high-throughput assay

06. Aug 2020 | 3 min read

COVID-19 antibody test: Development of a unique high-throughput assay

Particle-Enhanced Turbidimetric Immunoassay (PETIA) technology  creates an opportunity to significantly increase capacity for COVID-19/SARS-CoV-2 antibody testing, and importantly, at the same time make SARS-CoV-2 serology tests more easily available and affordable.

Gentian’s PETIA technology offers the benefits of cost-effective open platform testing, with shorter time-to-result and higher throughput compared to other immunoassay systems, perfectly responding to the increasing needs for SARS-CoV-2 antibody testing.

"Many IVD companies have already established COVID-19 antibody tests, however, these tests use assay technologies which usually result in a lower volume throughput. The Gentian antibody test will be a turbidimetric COVID-19 assay using the PETIA technology. The PETIA technology offers the benefits of cost-effective open platform testing, with shorter time-to-result and higher throughput compared to other immunoassay systems, perfectly responding to the envisaged testing needs for COVID-19"

Torsten Knüttel, VP R&D, Gentian

 

PETIA COVID-19/SARS-CoV-2 antibody test in development

Gentian has, over the last few months, worked in close cooperation with Professor Ørjan Olsvik and Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway.

Through this cooperation, we have completed some explorative test work that supports the concept of developing a turbidimetric SARS-CoV-2 antibody test based on Gentian’s proprietary technology. The immunoassay, if successfully developed, will be designed for use on high-throughput clinical chemistry analysers that are available in major laboratories around the world.

covid-patient_web-article2_web-ready

 

Proof-of-concept phase

The project is now in the proof-of-concept phase, with a strong focus on technical feasibility and market assessment to further specify the project and assay development. Subject to fulfillment of the criteria for this phase, the project intention is to undertake a fast track development with a planned launch in 2021.

Gentian has been awarded up to NOK 8.0 million of funding from the Research Council of Norway.

 

Want to know more?

Want to know more about the development of this immunoassay or other products from Gentian, please send an email to marketing@gentian.com or fill out the form below:

 

 

Investor news: https://ewsweb.oslobors.no/message/509241 

You may also read


Available position: Sales and Application Specialist, Stockholm

Sep 14, 2021

Available position: Sales and Application Specialist, Stockholm

Sales and Application Specialist, Stockholm Gentian Diagnostics AB has an exciting opportunity to offer a..

Calprotectin as an early marker to prevent sepsis

Sep 13, 2021

Calprotectin as an early marker to prevent sepsis

Sepsis Awareness Month and World Sepsis Day September is sepsis awareness month, and the 10th World Sepsis..

Gentian at AACC 2021

Sep 09, 2021

Gentian at AACC 2021

Meet us at #2021AACC  Gentian looks forward to meeting you at the AACC 2021. For its fifth consecutive year,..